159 related articles for article (PubMed ID: 10739874)
21. Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss.
Kaufman Y; Ifergan I; Rothem L; Jansen G; Assaraf YG
Blood; 2006 Apr; 107(8):3288-94. PubMed ID: 16368880
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biologic activity of new side-chain-altered methotrexate and aminopterin analogs with dual inhibitory action against dihydrofolate reductase and folylpolyglutamate synthetase.
Rosowsky A; Moran RG; Freisheim JH; Bader H; Forsch RA; Solan VC
NCI Monogr; 1987; (5):145-52. PubMed ID: 3431589
[TBL] [Abstract][Full Text] [Related]
23. Effect of a novel antifolate, N alpha-(4-amino-4-deoxypteroyl)-N delta-hemiphthaloyl-L-ornithine (PT523), on growth of H35 rat hepatoma and HEPG2 human hepatoma cells.
Rhee MS; Galivan J; Tyobeka EM; Sherman ML; Rosowsky A
Adv Exp Med Biol; 1993; 338():461-4. PubMed ID: 8304158
[No Abstract] [Full Text] [Related]
24. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
[TBL] [Abstract][Full Text] [Related]
25. Methotrexate analogues. 26. Inhibition of dihydrofolate reductase and folylpolyglutamate synthetase activity and in vitro tumor cell growth by methotrexate and aminopterin analogues containing a basic amino acid side chain.
Rosowsky A; Freisheim JH; Moran RG; Solan VC; Bader H; Wright JE; Radike-Smith M
J Med Chem; 1986 May; 29(5):655-60. PubMed ID: 2871191
[TBL] [Abstract][Full Text] [Related]
26. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
[TBL] [Abstract][Full Text] [Related]
27. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells.
Zhao R; Gao F; Goldman ID
Biochem Pharmacol; 2001 Apr; 61(7):857-65. PubMed ID: 11274972
[TBL] [Abstract][Full Text] [Related]
28. Methotrexate analogues. 31. Meta and ortho isomers of aminopterin, compounds with a double bond in the side chain, and a novel analogue modified at the alpha-carbon: chemical and in vitro biological studies.
Rosowsky A; Bader H; Forsch RA; Moran RG; Freisheim JH
J Med Chem; 1988 Apr; 31(4):763-8. PubMed ID: 3351853
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and in vitro antifolate activity of rotationally restricted aminopterin and methotrexate analogues.
Rosowsky A; Forsch RA; Wright JE
J Med Chem; 2004 Dec; 47(27):6958-63. PubMed ID: 15615544
[TBL] [Abstract][Full Text] [Related]
30. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.
McGuire JJ; Bergoltz VV; Heitzman KJ; Haile WH; Russell CA; Bolanowska WE; Kotake Y; Haneda T; Nomura H
Cancer Res; 1994 May; 54(10):2673-9. PubMed ID: 8168096
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and antifolate evaluation of the aminopterin analogue with a bicyclo.
Reynolds RC; Johnson CA; Piper JR; Sirotnak FM
Eur J Med Chem; 2001 Mar; 36(3):237-42. PubMed ID: 11337102
[TBL] [Abstract][Full Text] [Related]
32. Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo.
Holden SA; Teicher BA; Robinson MF; Northey D; Rosowsky A
Cancer Chemother Pharmacol; 1995; 36(2):165-71. PubMed ID: 7767954
[TBL] [Abstract][Full Text] [Related]
33. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
Mauritz R; Peters GJ; Kathmann I; Teshale H; Noordhuis P; Comijn EM; Pinedo HM; Jansen G
Cancer Chemother Pharmacol; 2008 Nov; 62(6):937-48. PubMed ID: 18283461
[TBL] [Abstract][Full Text] [Related]
34. Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. III. Synthesis and biological properties of N(omega)-masked ornithine analogs.
Itoh F; Yoshioka Y; Yukishige K; Yoshida S; Ootsu K; Akimoto H
Chem Pharm Bull (Tokyo); 2000 Sep; 48(9):1270-80. PubMed ID: 10993224
[TBL] [Abstract][Full Text] [Related]
35. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines.
Rothem L; Ifergan I; Kaufman Y; Priest DG; Jansen G; Assaraf YG
Biochem J; 2002 Nov; 367(Pt 3):741-50. PubMed ID: 12139489
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of N alpha-(4-amino-4-deoxy-10-methylpteroyl)-DL-4,4-difluoroornithine.
Tsukamoto T; Haile WH; McGuire JJ; Coward JK
J Med Chem; 1996 Jun; 39(13):2536-40. PubMed ID: 8691451
[TBL] [Abstract][Full Text] [Related]
37. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice.
Sirotnak FM; DeGraw JI; Colwell WT; Piper JR
Cancer Chemother Pharmacol; 1998; 42(4):313-8. PubMed ID: 9744777
[TBL] [Abstract][Full Text] [Related]
38. (6R,6S)-5,8,10-trideaza-5,6,7,8-tetrahydrofolate and 6(R,6S)-5,8,10-trideaza-5,6,7,8-tetrahydropteroyl-L-ornithine as potential antifolates and antitumor agents.
Rosowsky A; Forsch RA; Moran RG
J Med Chem; 1989 Mar; 32(3):709-15. PubMed ID: 2918520
[TBL] [Abstract][Full Text] [Related]
39. Folate transporter dynamics and therapy with classic and tumor-targeted antifolates.
O'Connor C; Wallace-Povirk A; Ning C; Frühauf J; Tong N; Gangjee A; Matherly LH; Hou Z
Sci Rep; 2021 Mar; 11(1):6389. PubMed ID: 33737637
[TBL] [Abstract][Full Text] [Related]
40. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
Backus HH; Pinedo HM; Wouters D; Padrón JM; Molders N; van Der Wilt CL; van Groeningen CJ; Jansen G; Peters GJ
Int J Cancer; 2000 Sep; 87(6):771-8. PubMed ID: 10956384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
